# US 2004/0062771 A1 · Clostridial toxin disease therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0062771 A1
- Document ID: US20040062771A1
- Status: Published application
- Kind: A1
- Application number: 10/662,918
- Filed: 2003-09-15
- Published: 2004-04-01
- Earliest claimed: 1989-10-31
- Assignees: Promega Corporation
- Inventors: Sean B. Carroll; Margaret B. van Boldrik; Christopher M. Clemens
- Web page: https://patentgrep.com/patent/US20040062771A1

## CPC

- C07K 14/33: from Clostridium (G)
- C07K 16/02: from eggs
- C07K 16/065: {Purification, fragmentation}
- C07K 16/1282: Clostridium (G)
- C07K 16/18: against material from animals or humans
- C07K 17/08: the carrier being a synthetic polymer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2317/11: isolated from eggs
- C07K 2317/23: from birds
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 424/804: involving IgG3, IgG4, IgA, or IgY
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.

## Claims

### Claim 1

A method, comprising:
a) providing:
i) a subject; and
ii) an orally administrable aqueous solution comprising avian antitoxin; and
b) orally administering said avian antitoxin to said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antitoxin comprises botulinus antitoxin.

### Claim 3 (depends on 1)

The method of claim 1, wherein said aqueous solution comprises a nutritional formula.

### Claim 4 (depends on 3)

The method of claim 3, wherein said nutritional formula comprises infant formula.
